Non-metastatic UTUC with RNU, n=532 (2000-2020)

High-risk patients (cT3-4 or cN+), n=289

- Low-risk n=236
- Concomitant radical cystectomy n=7

Ctrl group (RNU without NAC) n=145

NAC group (RNU with NAC) n=144
**Fig. S2**

**A** Visceral recurrence-free survival (n=289) (Unadjusted, 2000-2020)

- **Ctrl** n=145
- **NAC** n=144
- Exclusion: intravesical recurrence (pTa-1)

| Months | Ctrl | NAC |
|--------|------|-----|
| 0      | 145  | 144 |
| 12     | 140  | 143 |
| 24     | 135  | 142 |
| 36     | 130  | 141 |
| 48     | 125  | 139 |
| 60     | 120  | 137 |
| 72     | 115  | 135 |

**B** Cancer-specific survival (n=289) (Unadjusted, 2000-2020)

- **Ctrl** n=145
- **NAC** n=144
- P = 0.01

| Months | Ctrl | NAC |
|--------|------|-----|
| 0      | 145  | 144 |
| 12     | 140  | 143 |
| 24     | 135  | 142 |
| 36     | 130  | 141 |
| 48     | 125  | 139 |
| 60     | 120  | 137 |
| 72     | 115  | 135 |

**C** Overall survival (n=289) (Unadjusted, 2000-2020)

- **Ctrl** n=145
- **NAC** n=144
- P = 0.004

| Months | Ctrl | NAC |
|--------|------|-----|
| 0      | 145  | 144 |
| 12     | 140  | 143 |
| 24     | 135  | 142 |
| 36     | 130  | 141 |
| 48     | 125  | 139 |
| 60     | 120  | 137 |
| 72     | 115  | 135 |

**D** Visceral recurrence-free survival (n=178) (CKD3-4, Unadjusted)

- **Ctrl** n=99
- **Carboplatin-based** n=79
- P = 0.02

| Months | Ctrl | Carboplatin-based |
|--------|------|-------------------|
| 0      | 99   | 79                |
| 12     | 94   | 74                |
| 24     | 90   | 70                |
| 36     | 86   | 65                |
| 48     | 82   | 55                |
| 60     | 78   | 46                |
| 72     | 74   | 37                |

**E** Cancer-specific survival (n=178) (CKD3-4, Unadjusted)

- **Ctrl** n=99
- **Carboplatin-based** n=79
- P = 0.004

| Months | Ctrl | Carboplatin-based |
|--------|------|-------------------|
| 0      | 99   | 79                |
| 12     | 94   | 74                |
| 24     | 90   | 70                |
| 36     | 86   | 65                |
| 48     | 82   | 55                |
| 60     | 78   | 46                |
| 72     | 74   | 37                |

**F** Overall survival (n=178) (CKD3-4, Unadjusted)

- **Ctrl** n=99
- **Carboplatin-based** n=79
- P = 0.01

| Months | Ctrl | Carboplatin-based |
|--------|------|-------------------|
| 0      | 99   | 79                |
| 12     | 94   | 74                |
| 24     | 90   | 70                |
| 36     | 86   | 65                |
| 48     | 82   | 55                |
| 60     | 78   | 46                |
| 72     | 74   | 37                |

**G** Visceral recurrence-free survival (Unadjusted, NAC group n=144)

- **Cisplatin-based** n=38
- **Carboplatin-based** n=106
- P = 0.056

| Months | Cisplatin-based | Carboplatin-based |
|--------|-----------------|-------------------|
| 0      | 38              | 106               |
| 12     | 33              | 101               |
| 24     | 28              | 96                |
| 36     | 23              | 89                |
| 48     | 19              | 82                |
| 60     | 8               | 75                |
| 72     | 2               | 68                |

**H** Cancer-specific survival (Unadjusted, NAC group n=144)

- **Cisplatin-based** n=38
- **Carboplatin-based** n=106
- P = 0.679

| Months | Cisplatin-based | Carboplatin-based |
|--------|-----------------|-------------------|
| 0      | 38              | 106               |
| 12     | 33              | 101               |
| 24     | 28              | 96                |
| 36     | 23              | 89                |
| 48     | 19              | 82                |
| 60     | 8               | 75                |
| 72     | 2               | 68                |

**I** Overall survival (Unadjusted, NAC group n=144)

- **Cisplatin-based** n=38
- **Carboplatin-based** n=106
- P = 0.569

| Months | Cisplatin-based | Carboplatin-based |
|--------|-----------------|-------------------|
| 0      | 38              | 106               |
| 12     | 33              | 101               |
| 24     | 28              | 96                |
| 36     | 23              | 89                |
| 48     | 19              | 82                |
| 60     | 8               | 75                |
| 72     | 2               | 68                |